Compliance in depressed patients treated with fluoxetine or amitriptyline

International Clinical Psychopharmacology

Volumn 13, Issue 1, 1998, Pages 11-17

  Demyttenaere, K ^a   Van Ganse, E ^b   Gregoire, J ^c   Gaens, E ^d   Mesters, P ^d   Reynaert, C ^e   Zdanowicz, N ^e   Janne, P ^e   Jannes, S ^e   Spiers, R ^e   Cosijns, P ^e   Verbruggen, W ^e   Castro, P ^e   Nefve, C ^e   Lebrun, T ^e   Roussaux, J P ^e   Luts, A ^e   D'Haenen, H ^e   Gavart, S ^e   Wallyn, K ^e   Taymans, J ^e   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITÉ DE LYON   (France)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d Eli Lilly Benelux   (Belgium)

^e Department of Psychiatry ^*

Author keywords

Adherence; Amitriptyline; Compliance; Fluoxetine

Indexed keywords

AMITRIPTYLINE; FLUOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; DRUG USE; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONITORING; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; REGRESSION ANALYSIS; SIDE EFFECT;

EID: 15144345237     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199801000-00002     Document Type: Article

References (20)

1. Agras WS (1989). Understanding compliance with the medical regimen: the scope of the problem and a theoretical perspective. Arthritis Care and Research 2:S2-S7.
2. Blackwell B (1992). Compliance. Psychotherapy and Psychosomatics 58:161-169.
3. Demyttenaere K (1997). Compliance during treatment with antidepressants. J Affect Disord 43:27-39.
4. Demyttenaere K, Vanderschueren D (1995). Selective serotonin reuptake inhibitors and sexual functions. In: Bancroft J, ed The pharmacology of sexual function and dysfunction. Elsevier Publishing, Amsterdam. pp. 327-339.
5. Fawcett J (1995). Compliance: definitions and key issues. J Clin Psychiatry 56 (suppl 1):4-8.
6. Greden JF (1993). Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 54 (suppl 8):39-45.
7. Gryfe CI, Gryfe B (1984). Drug therapy of the aged: the problem of compliance and the rules of physicians and pharmacists. J Am Geriatr Soc 32:301-307.
8. Kruse W, Weber E (1990). Dynamics of drug regimen compliance - its assessment by microprocessor-based monitoring. EurJClin Pharmacol 38:561-565.
9. Kupfer D, Frank E, Perel J, Cornes C, Mallinger A, Thase M, et al. (1992). Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769-773.
10. Le Pen C, Levy E, Ravily V, Beuzen JN, Meurgey F (1994). The cost of treatment dropout in depression. A cost-benefit analysis of fluoxetine versus tricyclics. J Affect Disord 31:1-18.
11. Lorenc L, Branthwaite A (1993). Are older adults less compliant with prescribed medication than younger adults? Br J Clin Psychol 32:485-492.
12. Madsen WC (1992). Problematic treatment: interaction of patient, spouse, and physician beliefs in medical noncompliance. Family Systems Medicine 10:365-383.
13. Montgomery SA, Dufour H, Brion S, Bailledrena J, Laqueille X, Ferrey G (1988). The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 153 (suppl 3):69-76.
14. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, et al. (1994). Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
15. Myers ED, Branthwaite A (1992). Out-patient compliance with antidepressant medication. Br J Psychiatry 160:83-86.
16. Nicholson WA (1967). Collection of unwanted drugs from private homes. BMJ iii:730.
17. Pande AC, Sayler ME (1993). Adverse events and treatment discontinuations in fluoxetine clinical trials. Int Clin Psychopharmacol 8:267-269.
18. Quitkin FM (1985). The importance of dosage in prescribing antidepressants. Br J Psychiatry 147:593-597.
19. Trostle JA (1988). Medical compliance as an ideology. Social Sciences and Medicine 27:1299-1308.
20. Walle T, Walle UK, Conradu EC (1989). Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects. Clinical Pharmacological Therapy 46:257-263.